Q1 Earnings Estimate for ETON Issued By B. Riley

Eton Pharmaceuticals, Inc. (NASDAQ:ETON) – B. Riley issued their Q1 2025 earnings per share (EPS) estimates for Eton Pharmaceuticals in a research report issued on Thursday, January 9th. B. Riley analyst M. El-Saadi anticipates that the company will post earnings of $0.03 per share for the quarter. B. Riley has a “Strong-Buy” rating on the stock. The consensus estimate for Eton Pharmaceuticals’ current full-year earnings is ($0.17) per share. B. Riley also issued estimates for Eton Pharmaceuticals’ Q4 2025 earnings at $0.12 EPS.

A number of other brokerages have also recently commented on ETON. HC Wainwright lifted their target price on shares of Eton Pharmaceuticals from $15.00 to $17.00 and gave the stock a “buy” rating in a research report on Monday, January 6th. Craig Hallum lifted their price objective on Eton Pharmaceuticals from $15.00 to $18.00 and gave the stock a “buy” rating in a report on Wednesday, January 8th.

Eton Pharmaceuticals Price Performance

Shares of NASDAQ ETON opened at $13.44 on Monday. The stock has a market capitalization of $350.13 million, a P/E ratio of -61.09 and a beta of 1.38. Eton Pharmaceuticals has a one year low of $3.03 and a one year high of $15.00. The firm’s 50 day simple moving average is $11.74 and its two-hundred day simple moving average is $7.48.

Institutional Investors Weigh In On Eton Pharmaceuticals

A number of large investors have recently added to or reduced their stakes in the company. Westside Investment Management Inc. grew its stake in shares of Eton Pharmaceuticals by 5.7% in the third quarter. Westside Investment Management Inc. now owns 618,675 shares of the company’s stock worth $3,711,000 after purchasing an additional 33,275 shares during the last quarter. Geode Capital Management LLC lifted its holdings in Eton Pharmaceuticals by 13.5% in the 3rd quarter. Geode Capital Management LLC now owns 272,696 shares of the company’s stock worth $1,637,000 after buying an additional 32,365 shares during the period. Jane Street Group LLC bought a new stake in shares of Eton Pharmaceuticals in the 3rd quarter worth approximately $90,000. Parkman Healthcare Partners LLC raised its holdings in shares of Eton Pharmaceuticals by 2.8% during the third quarter. Parkman Healthcare Partners LLC now owns 260,226 shares of the company’s stock valued at $1,561,000 after acquiring an additional 7,029 shares in the last quarter. Finally, Point72 Asia Singapore Pte. Ltd. purchased a new stake in Eton Pharmaceuticals in the third quarter worth $54,000. Institutional investors own 27.86% of the company’s stock.

Eton Pharmaceuticals Company Profile

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.